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To determine the role of viral burden in simian–human immunodeficiency virus (SHIV)-induced disease, cellular provirus
and plasma viral RNA levels were measured after inoculation of rhesus monkeys with four different SHIVs. These SHIVs
included SHIV-HXBc2 and SHIV-89.6, constructed with env, tat, rev, and vpu derived from either cell line-passaged or primary
patient isolates of human immunodeficiency virus type 1; the viral quasispecies SHIV-89.6P derived after in vivo passage of
SHIV-89.6; and a molecular clone, SHIV-KB9, derived from SHIV-89.6P. SHIV-HXBc2 and SHIV-89.6 are nonpathogenic in
rhesus monkeys; SHIV-89.6P and SHIV-KB9 cause rapid CD41 T cell depletion and an immunodeficiency syndrome. Relative
SHIV provirus levels were highest during primary infection in monkeys infected with SHIV-89.6P, the virus that caused the
most rapid and dramatic CD41 T cell depletion. However, by 10 weeks postinoculation, provirus levels were similar in
monkeys infected with the pathogenic and nonpathogenic chimeric viruses. The virus infections that resulted in the highest
peak and chronic viral RNA levels were the pathogenic viruses SHIV-89.6P and SHIV-KB9. SHIV-89.6P uniformly caused rapid
and profound CD41 T cell depletion and immunodeficiency. Infection with the SHIV-KB9 resulted in very low CD41 T cell
counts without seroconversion in some monkeys and a substantial but less profound CD41 T cell depletion and rapid
seroconversion in others. Surprisingly, the level of plasma viremia did not differ between SHIV-KB9-infected animals
exhibiting these contrasting outcomes, suggesting that host factors may play an important role in AIDS virus pathogenesis.
© 1999 Academic Press
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HINTRODUCTION
The kinetics of human immunodeficiency virus type
(HIV-1) replication is a central determining factor in
IDS progression. The study of virologic events after
xperimental inoculation of macaques with the simian
IDS viruses has proved to be useful for addressing
uestions in AIDS pathogenesis. The nonhuman pri-
ate models have also been used to assess HIV
accine approaches where virologic events and dis-
ase progression can serve as a measure of vaccine
fficacy.
The chimeric simian–human immunodeficiency vi-
uses (SHIVs) have been particularly useful tools for
efining the role of envelope glycoproteins in AIDS
athogenesis and for assessing HIV-1 Env-based vac-
ines. In contrast to infection with the simian immu-
odeficiency viruses, infection of macaques with some
athogenic SHIV variants causes a unique, acute
D41 T cell loss and results in an AIDS-like immuno-
1 To whom reprint requests should be addressed at Beth Israel
eaconess Medical Center, RE-113, P.O. Box 15732, Boston, MA 02215.iax: (617) 667-8210. E-mail: kreimann@caregroup.harvard.edu.
15eficiency syndrome (Harouse et al., 1998; Joag et al.,
996; Reimann et al., 1996b; Shibata et al., 1997).
hese chimeric viruses have proved instrumental in
lucidating molecular determinants of CD41 T cell
epletion (Karlsson et al., 1998) and will allow CD41 T
ell loss and disease induction to be used as an end
oint in testing HIV-1 Env-based vaccines. With the
ncreasing use of SHIV models to test the efficacy of
ew vaccine strategies, it will be important to under-
tand the virologic events in monkeys infected with
hese viruses. This knowledge will facilitate choosing
ptimal challenge viruses for vaccine studies and us-
ng SHIV replication as an early surrogate marker of
accine efficacy.
In the present study, we evaluated rhesus monkeys
noculated with three SHIV molecular clones and one
iological SHIV isolate to determine the association
etween viral burden and pathogenicity. We show that
he chimeric viruses with the greatest potential for
D41 T cell depletion exhibited the highest levels of
irus replication during primary and chronic infection.
owever, variability in disease course in monkeysnfected with the same pathogenic molecular clone of
0042-6822/99 $30.00
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16 REIMANN ET AL.HIV was not due solely to differences in virus repli-
ation rates.
RESULTS AND DISCUSSION
linical outcome of SHIV infections
The clinical sequelae of infection with three molecular
HIV clones and one biological SHIV isolate have been
valuated in rhesus monkeys. The characterization of
hese viruses and the clinical outcome of infection are
ummarized in Table 1 and Fig. 1. SHIV-HXBc2, con-
tructed with the env and associated auxiliary genes of a
cell line-passaged HIV-1, persistently infected rhesus
onkeys but caused no decline in CD41 T cell number.
onkeys inoculated with this virus have remained
T
Derivation and Patho
SHIV construct Derivation Pathogenicity in
SHIV-HXBc2 SIVmac239 with env, tat, rev,
and vpu from HIV-1-
HXBc2
Persistent infection
SHIV-89.6 SHIV-HXBc2 with env from
HIV-1-89.6
Persistent infection
SHIV-89.6P Biologic isolate obtained
after four serial in vivo
passages of SHIV-89.6
Profound, persiste
depletion and A
SHIV-KB9 Molecular clone from
SHIV-86.9P
Rapid CD41 T cell
partial recovery
monkeys whose
to recover
FIG. 1. Relative change in number of peripheral blood CD41 T cells
n rhesus monkeys after intravenous inoculation with SHIV-HXBc2 (F),
HIV-89.6 (M), SHIV-89.6P (), or SHIV-KB9 (f). Data are expressed as
edian percent change from preinoculation values, n $ 4 monkeys forrach virus infection.ealthy for .3 years after infection (Li et al., 1995).
nfection of monkeys with SHIV-89.6, constructed with
he HIV-1 envelope from the primary HIV-1 isolate 89.6,
aused at most a transient loss of CD41 T cells
Reimann et al., 1996a). Monkeys persistently infected
ith this virus have also remained healthy for .3 years.
he biological viral isolate SHIV-89.6P was derived
hrough four serial in vivo passages of SHIV-89.6 in
hesus monkeys (Reimann et al., 1996b). The molecular
lone SHIV-KB9 was derived from the monkey used for
he fourth animal passage of SHIV-89.6 that resulted in
HIV-89.6P (Karlsson et al., 1997). Infection of rhesus
onkeys with SHIV-89.6P and SHIV-KB9 consistently re-
ults in a rapid and persistent CD41 T cell loss, predis-
osing to opportunistic infections and an AIDS-like dis-
ase. We wanted to determine the relationship between
iral burden and the pathogenicity of these different
iruses.
rovirus levels in infected monkeys
Provirus copy number was determined in PBMCs and
ymph node mononuclear cells at various times after
HIV inoculation. To provide a point of reference with a
ell characterized pathogenic virus, specimens were
lso obtained from rhesus monkeys inoculated with the
imian immunodeficiency virus of macaques (SIVmac)
solate 251. Proviral copy number was determined in
NA extracted from these specimens using a quantita-
ive PCR technique. The fraction of cells that were CD41,
nd thus the potential reservoirs of SHIV infection, varied
onsiderably between specimens. Therefore, proviral
opy number for each specimen was normalized for the
raction of cells that were CD41 and data expressed as
y of Chimeric SHIV
monkeys
Immune responses elicited
during infection Reference
disease Neutralizing antibodies and
CTL
Li et al. (1992)
Li et al. (1995)
Reimann et al. (1996a)
Montefiori et al. (1998)
disease Neutralizing antibodies and
CTL
Reimann et al. (1996a)
Montefiori et al. (1998)
T cell No neutralizing antibodies
or CTL
Reimann et al. (1996b)
Montefiori et al. (1998)
ion with
e; AIDS in
T cells fail
Neutralizing antibodies and
CTL in monkeys showing
partial CD41 T cell
recovery; no neutralizing
antibodies or CTL in
monkeys that fail to
recover CD41 T cells
Karlsson et al. (1997)
Montefiori et al. (1998)ABLE 1
genicit
rhesus
but no
but no
nt CD41
IDS
deplet
in som
CD41elative copy number. During primary infection, signifi-
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17IN VIVO REPLICATION OF CHIMERIC SHIV VARIANTSantly higher provirus levels were detected in monkeys
nfected with the rapidly CD41 T cell-depleting SHIV-
9.6P (Fig. 2). Provirus levels in PBMCs of monkeys
nfected with nonpathogenic SHIV-89.6 were similar to
hose observed in monkeys infected with pathogenic
IVmac-infected monkeys. Interestingly, by 10 weeks
ostinoculation, PBMC provirus levels in nonpathogenic
HIV-89.6-infected monkeys were similar to those ob-
erved in monkeys infected with pathogenic SHIV-89.6P
nd SIVmac. Provirus levels in PBMCs of monkeys in-
ected with SHIV-HXBc2 were consistently lower but not
ignificantly different from those of monkeys infected
ith the other three viruses. Viral DNA levels in lymph
ode cells paralleled those measured in PBMCs but
ere, on average, 1.5 times higher (data not shown).
hus provirus copy number was highest during primary
nfection in SHIV-89.6P, the virus that caused the most
apid depletion of CD41 T cells. However, during chronic
nfection, provirus copy number did not strongly correlate
ith persistent CD41 T cell loss or pathological outcome
f virus infection in SHIV-infected monkeys.
lasma viral RNA levels in infected monkeys
Virus replication in monkeys inoculated with the vari-
us SHIVs and SIVmac was determined by measuring
iral RNA concentration in plasma. The two different
ssay methods used in these studies, quantitative-com-
etitive (QC)-PCR and branched DNA amplification
bDNA) assays, gave equivalent results when used to
nalyze the same specimens (Fig. 3). Therefore, data
btained using both assay methods were pooled. Spec-
mens were collected during peak virus replication
10–14 days postinoculation), at 5–6 weeks postinocula-
FIG. 2. Relative provirus copy number in PBMCs obtained from SHIV-
nd SIVmac-infected rhesus monkeys. DNA from PBMCs obtained after
nfection with SHIV-HXBc2 (F), SHIV-89.6 (M), SHIV-89.6P (), or SIV-
ac (E) was assayed for provirus copy number using a quantitative
CR technique. To adjust for varying numbers of CD41 T cells in
BMCs, copy number was divided by percent of CD41 T cells to yield
relative copy number. Median value, n 5 2–4 for each virus infection
t each time point. *Significantly different, P , 0.05.ion, and at 10 weeks postinoculation, when viral repli- aation rates had reached a plateau. As shown in Fig. 4A,
he highest levels of virus replication during primary
nfection were seen in monkeys infected with the patho-
enic viruses SHIV-89.6P, SHIV-KB9, and SIVmac. Of
hese three high replicating viruses, SHIV-89.6P infection
esulted in peak viral RNA levels significantly higher than
hose associated with SIVmac infection. SHIV-HXBc2-
nfected monkeys had peak viral loads that were 1–3 log
ower than that in monkeys infected with the other vi-
uses. Monkeys inoculated with the nonpathogenic
HIV-89.6 had intermediate peak plasma viral RNA levels
hat were significantly higher than those of SHIV-HXBc2-
nfected monkeys but significantly lower that monkeys
nfected with pathogenic viruses. By 5–6 weeks postin-
culation, virus replication had decreased substantially
n all animals (Fig. 4B). However, at 10 weeks postinocu-
ation, virus replication persisted at high levels (median
iral loads, 105-106 copies/ml) in all monkeys infected
ith SIVmac and SHIV-89.6P and four of five monkeys
nfected with SHIV-KB9 (Fig. 4C). These results suggest
hat viruses capable of causing acute CD41 T cell loss
eplicate to higher levels during primary infection than
hose that cause chronic CD41 T cell loss. However,
ersistent replication at 10 weeks postinoculation was a
haracteristic shared by all of the pathogenic viruses
egardless of whether they caused rapid or gradual
D41 T cell depletion.
ariation in clinical course of monkeys infected with
HIV-KB9
More than 20 monkeys inoculated with the biologic
solate SHIV-89.6P have developed a remarkably uniform
isease course (unpublished observation). The clinical
ourse is characterized by a rapid and profound CD41 T
FIG. 3. Plasma viral RNA levels measured by QC-PCR or bDNA
ethods show good correlation. Plasma specimens obtained from
IVmac- or SHIV-89.6P-infected rhesus monkeys were divided and
nalyzed by QC-PCR and bDNA methods as described in the text. r2 5
.92; mean difference 5 0.05 6 0.35 (S.D.). Results are consistent with
1:1 linear relationship with slope 5 1 (P , 0.05).
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18 REIMANN ET AL.ell decline, usually to ,50 cells/ml, by 14 days postin-
culation. These animals failed both to seroconvert
Montefiori et al., 1998) and to develop virus-specific
ytotoxic T lymphocyte responses (unpublished obser-
ation). Surprisingly, monkeys inoculated with the molec-
FIG. 4. Viral RNA levels in plasma of SHIV- and SIVmac-infected
hesus monkeys. Levels during peak viremia (A) were determined on
lasma specimens obtained 10–14 days after virus inoculation. Viral
NA levels declined by 5–6 weeks postinoculation in all animals (B)
nd remained detectable at 10 weeks only in those animals infected
ith viruses that cause CD41 T cell depletion and immunodeficiency
C). Data are expressed as median 6 range. Limit of detection: 10,000
NA copies/ml. *No significant difference between indicated groups.lar clone SHIV-KB9, derived from a monkey infected rith the SHIV-89.6P quasispecies, showed two distinct
linical outcomes. Of 15 monkeys that were inoculated
ith SHIV-KB9, 5 have developed a disease course sim-
lar to that seen in monkeys infected with SHIV-89.6P.
ithin 2–3 weeks after inoculation, CD41 T counts in
hese animals reached a nadir of ,50 cells/ml (Fig 5A).
D41 T cell counts never substantially recovered, and
onkeys did not seroconvert (end point, anti-SHIV titer
1:100). In contrast, 10 of 15 SHIV-KB9-infected monkeys
ave reached CD41 T cell nadirs of .50 cells/ml after
noculation, and CD41 T cell counts partially recovered
ut consistently remain at ,50% of preinfection levels
Fig. 5B). These animals developed strong antiviral anti-
ody responses, and those antibodies tested neutralized
HIV-KB9 (Montefiori et al., 1998). The variability in clin-
cal outcome seen in monkeys inoculated with the
loned SHIV-KB9 compared with SHIV-89.6P infection
as unexpected. Inoculation with a viral quasispecies
ay favor the rapid selection of a higher replicating and
FIG. 5. CD41 T cell counts and anti-SHIV antibody titers in rhesus
onkeys infected with SHIV-KB9 demonstrating different clinical out-
omes. (A) Those monkeys whose CD41 T cell nadir after inoculation
as ,50 cells/ml failed to substantially recover CD41 T cell number
nd did not seroconvert. (B) Monkeys whose blood CD41 T cell nadir
fter inoculation was .50 cell/ml demonstrated partial CD41 T cellecovery and seroconverted.
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19IN VIVO REPLICATION OF CHIMERIC SHIV VARIANTSore acutely pathogenic viral variant than does inocula-
ion with a single cloned viral species. However, the
ariability in disease course seen with SHIV-KB9 infec-
ion was similar to that observed in monkeys inoculated
ith a biological isolate closed related to SHIV-89.6P
SHIV-89.6PD) (Steger et al., 1998) that had been isolated
nd expanded in a T cell line (Lu et al., 1998).
We used monkeys infected with SHIV-KB9 to deter-
ine whether the clinical outcome of infection was as-
ociated with the magnitude of virus replication during
rimary or chronic infection. Plasma viral RNA levels
ere measured in seven monkeys during primary SHIV-
B9 infection and at 10–12 weeks after virus inoculation
sing a more sensitive bDNA assay. As shown in Fig. 6,
he animals with the highest levels of plasma viremia
uring primary infection also had the highest levels of
lasma viremia during chronic infection. However,
lasma viral RNA levels during either primary or chronic
nfection did not differ between the SHIV-KB9-infected
onkeys with lower CD41 T cell counts that did not
eroconvert and those with less profound CD41 T cell
epletion and evidence of rapid seroconversion. This
bservation suggests that in addition to the level of virus
eplication, individual host determinants contribute to the
mmunopathogenesis of SHIV-induced disease.
The relationship between level of HIV-1 replication and
isease progression in infected humans is well estab-
ished (Mellors et al., 1996). A similar relationship be-
ween viral load and disease course has been seen in
FIG. 6. Plasma viral RNA levels in rhesus monkeys infected with
HIV-KB9. Plasma viral RNA levels were measured during primary
iremia (A) and at .10 weeks after SHIV-KB9 inoculation (B). Infected
onkeys were divided in two groups: those with profound CD41 T cell
epletion and failure to seroconvert (Low CD4) and those with higher
D41 T cell counts that developed strong anti-SHIV antibody titers
High CD4). Each symbol represents one animal. Limit of detection:
500 copies/ml.acaque monkeys infected with pathogenic SIV pChakrabarti et al., 1994; Lifson et al., 1997; Watson et al.,
997). In other SHIV constructs, animal passage or ge-
etic modifications of the viruses that resulted in the
cquisition of pathogenicity were always associated with
ncreased rates of viral replication (Joag et al., 1996;
hibata et al., 1997). We report that the pathogenic vi-
uses derived from SHIV-89.6 all maintain higher replica-
ion rates than the nonpathogenic viruses from which
hey were derived. Moreover, SHIV-89.6P, the virus with
he greatest potential for causing acute CD41 T cell loss,
howed the highest replication rates during primary in-
ection. Although these data strongly suggest that viral
urden is one determining factor in SHIV-induced patho-
enesis, other studies using molecular clones have
hown that changes in the intrinsic CD41 T cell-
epleting ability have also occurred with SHIV-89.6P pas-
age (Karlsson et al., 1998).
Because the highest rates of SHIV replication during
rimary infection were associated with rapid CD41 T cell
oss, suppression of virus replication during this time
ay affect disease course. Lower levels of primary SIV-
ac viremia, whether they occurred naturally or in re-
ponse to experimental immunization, were associated
ith a significantly slower disease course (Hirsch et al.,
996; Lifson et al., 1997; Watson et al., 1997). Therefore, it
s reasonable to assume that manipulations to control
rimary SHIV viremia could attenuate acute CD41 T cell
epletion seen in SHIV-89.6P or SHIV-KB9 infection.
The ideal HIV-1 vaccine would induce sterilizing im-
unity capable of blocking infection of the host after
irus exposure. However, vaccines that cannot provide
rotective immunity might elicit cellular or humoral re-
ponses that modulate early HIV-1 replication and pro-
ong survival in those who do become infected. It is
herefore important to have animal models for HIV-1
accine protection that provide a rapid and quantifiable
ssessment of the impact of immunization on a virus
eplication and clinical sequelae to infection. The patho-
enic SHIVs provide such models for AIDS vaccine test-
ng where rates of virus replication and extent of CD41 T
ell decline can be accurately measured after vaccina-
ion and challenge.
MATERIALS AND METHODS
iruses
The viruses used in this study and the clinical outcome
f infection of rhesus monkeys with each are summa-
ized in Table 1. SHIV-HXBc2 (previously called SHIV-4)
as constructed from SIVmac 239 (nef open) plasmids
odified to contain env, tat, rev, and vpu derived from the
IV-1 clone HXBc2 (Li et al., 1992) and has a functional
IV-1 vpu. SHIV-89.6 was derived from the SHIV-HXBc2
lasmids after a fragment containing env and rev from
he primary isolate HIV-1 clone, 89.6, was used to re-
lace the equivalent fragment deleted from the parental
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20 REIMANN ET AL.lasmid. This construct encodes chimeric (89.6/HXBc2)
p41 envelope glycoprotein and Rev protein (Reimann et
l., 1996a). SHIV-89.6P is a biologic isolate derived from
rimary lymphocyte culture after SHIV-89.6 was pas-
aged serially four times in rhesus monkeys (Reimann et
l., 1996b). SHIV-KB9 is a clone derived after the fourth
assage of SHIV-89.6P (Karlsson et al., 1998). SIVmac251
s a low-passage biological isolate (Kannagi et al., 1985).
nimal inoculations
In all studies, rhesus monkeys (Macaca mulatta) were
noculated intravenously with viruses grown in CEMx174
ells (SHIV-KB9) or in rhesus monkey PBMCs (SHIV-
XBc2 and SHIV-89.6). We previously reported the pre-
ominant immunological and virologic features observed
uring primary infection of all eight rhesus monkeys with
HIV-HXBc2 or SHIV-89.6 (Reimann et al., 1996a) and two
f the seven monkeys with SHIV-KB9 (Karlsson et al.,
998) that are described in detail herein. SHIV-89.6P was
rown in primary rhesus monkey lymphocyte cultures.
IVmac251 was grown in human lymphocytes. Monkey
noculated with these viruses received 10–1000 animal
nfectious doses. All animals were maintained in accor-
ance with the guidelines of the Committee on Animals
or the Harvard Medical School and the “Guide for the
are and Use of Laboratory Animals” (National Research
ouncil, National Academic Press, Washington, DC,
996).
D41 T cell counts
Peripheral blood lymphocytes were immunopheno-
yped using CD4- (OKT4; Ortho Diagnostic Systems, Rari-
an, NJ) and CD3- (SP34; PharMingen, San Diego, CA)
pecific antibodies by flow cytometry using a standard
hole blood lysis technique. Absolute lymphocyte
ounts were derived from an automated hematology an-
lyzer (T540; Beckman Coulter, Miami, FL).
nti-SHIV antibody titers
Antibody titers in SHIV-KB9-infected monkeys were
etermined using a commercial kit [HIVAB HIV-1 EIA
3A11); Abbott Laboratories, Abbott Park, IL]. EDTA
lasma specimens were serially diluted starting at 1:100
ilution and routinely assayed. End point titer was deter-
ined as the highest dilution to give a positive result.
uantification of SHIV provirus
A quantitative PCR assay was performed on DNA
xtracted from PBMCs or lymph node lymphocytes of
HIV- or SIV-infected monkeys using a method similar to
hat previously described (Reimann et al., 1995). Briefly,
00 ng of DNA was amplified through 30 cycles (1 min
0°C, 1 min 72°C) using primers to produce a 200-bp
roduct from the gag/pol region of SIVmac. Parallel sam-le tubes were run with primers for rhesus monkey CD4
hat produced a 333-bp product to control for DNA load-
ng. DNA (200 ng) was added in a volume of 20 ml. PCR
roducts were electrophoresed through a 2% agarose
el, transferred to a nylon membrane, and hybridized
ith an internal probe labeled with 32P. Quantification
as performed with a gel scan program by comparison
ith a standard curve generated from a gag/pol fragment
f known concentration. To adjust for varying CD41 T cell
umber in the specimens, the provirus copy number per
00 ng of DNA was divided by the percent CD41 T cells
s determined by immunophenotyping as described
bove.
uantification of plasma viral RNA
Two different methods of quantifying plasma viral RNA
ere used in this study. For some specimens, a QC-PCR
ethod developed for SIVmac was used as previously
escribed (Watson et al., 1997). Primers used in this
ssay hybridized with SIV gag, which was conserved in
ll the variant SHIVs. Briefly, plasma RNA was extracted
nd then reverse transcribed in the presence of 500
opies of a competitor RNA. These reaction products
ere amplified by PCR and separated on agarose gel.
he viral RNA yielded a 336-bp band, and the control
ielded a 253-bp band. Viral RNA levels were calculated
rom the dilution of sample that produced a visual signal
quivalent to the internal control.
For other specimens, measurement of viral RNA in
lasma was performed by Chiron Diagnostics (Em-
ryville, CA) using a branched DNA amplification assay
imilar to the Quantiplex HIV-RNA branched DNA assay
Pachl et al., 1995). Target probes were designed to
ybridize with the pol region of SIVmac and therefore can
e used to quantify SHIV viral RNA. Results were quan-
ified by comparison with purified and quantified in vitro-
ranscribed SIV pol RNA.
tatistical analysis
Relative provirus and plasma viral RNA levels were
og10 transformed, resulting in data that were sufficiently
ormalized to use standard parametric tests. Overall,
ifferences between groups were tested using analysis
f variance, followed by post-hoc testing with the Stu-
ent–Newman–Keuls multiple-comparison procedure
hen the overall test indicated significant differences
etween groups. P , 0.05 was used for statistical sig-
ificance.
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